ENvue Medical, Inc.
envuemed.comWhat Do They Do?
Sells home-use devices targeting biofilm prevention, pain therapy and wound healing, and feeding-tube navigation systems and related products for hospitals.
10-K for FY2025, filed Apr 15, 2026We were organized as a Delaware corporation in October 2003. On February 14, 2025, we completed the Merger pursuant to the Merger…View ↗
ENvue is a medical device company engaged in the research, development, production, marketing, and sale of medical devices in the field of…View ↗
In addition to feeding tubes, the Company offers enteral feeding accessories, including syringes and other related products intended to…View ↗
How Do They Make Money?
NanoVibronix sells products through distributors and its website; ENvue sells navigation systems and feeding tubes to hospitals, which typically pay after delivery.
10-K for FY2025, filed Apr 15, 2026CustomersView ↗
ENvue’s current and potential customers are hospitals in the U.S. As of 2023, there are approximately 5,222 hospitals in the U.S. that…View ↗
Under ENvue’s agreements with customers for the purchase of the ENvue System, ENvue commits to manufacture, assemble, and supply the system…View ↗
-
10-K for FY2025, filed Apr 15, 2026
FY2025 revenue by reportable segment ↗
$2.6M
-
10-K for FY2025, filed Apr 15, 2026
$2.6M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Nano Vibronix
|
73% |
Nano Vibronix, FY2025
$1.9M Sources
|
|
|
ENvue
Sold outright
10-K for FY2025, filed Apr 15, 2026 |
27% |
ENvue, FY2025
$696K Sources
|
Sold outright |
Who Are Their Customers?
NanoVibronix sells through medical-product distributors and sales agents, with consumers also buying through its website; ENvue sells directly to U.S. hospitals.
10-K for FY2025, filed Apr 15, 2026CustomersView ↗
ENvue’s current and potential customers are hospitals in the U.S. As of 2023, there are approximately 5,222 hospitals in the U.S. that…View ↗
ENvue is in the stage of commercializing its products, and its sales activities in the U.S. were conducted directly with end customers. As…View ↗
10-K for FY2025, filed Apr 15, 2026
We currently sell our products both directly through our website and indirectly via distribution agreements, with approximately 98% of our…View ↗
Do Revenues Turn Into Profits?
No. It lost $18.2M in FY2025.
10-K for FY2025, filed Apr 15, 2026
−$22.9MView ↗
10-K for FY2025, filed Apr 15, 2026
−$18.2MView ↗
10-K for FY2025, filed Apr 15, 2026
−$9.4MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 17, 2026
−$4.9MView ↗
- ▲ +23% (Loss)
- vs −$4M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 17, 2026
Open tableView ↗
-
Jul 14, 2026
Zeev Rotstein was appointed board chair
The board appointed Prof. Rotstein as its new chairman.
Sources
8-K, filed Jul 14, 2026
In addition, Prof. Rotstein was appointed to serve as the new Chairman of the Board.View ↗
-
Jul 10, 2026
Nasdaq found the company noncompliant with its minimum bid-price rule
The company said it would request a hearing; a timely request stays suspension or delisting pending the panel's decision.
Sources
8-K, filed Jul 10, 2026
On July 10, 2026, ENvue Medical, Inc. (the “Company”) received a letter (the “Staff Determination Letter”) from the Listing Qualifications…View ↗
Growing. Revenue grew 51% in 4 years, from $1.7M in FY2021 to $2.6M in FY2025, about 11% a year.
Loading...
